Oscar Health, Inc. (OSCR)

Oscar Health presents a compelling case for a momentum-driven entry, though investors must navigate significant valuation concerns. The stock has rallied nearly 70% over the last quarter, driven by a dramatic turnaround in profitability where revenue growth finally translated into a 34% return on equity and a 7% operating margin. Fundamentally, the business is turning the corner with a fortress-like balance sheet holding over $8 billion in cash against minimal debt, and a forward P/E of 17x suggests the market is pricing in continued expansion. However, the price has already run up significantly, trading near its 52-week high, which creates a crowded trade environment. While the statistical forecast models offer only a weak lean upward due to recent volatility, the options market is screaming bullishness, with heavy call buying establishing a floor around $35. The lack of a dividend yield is irrelevant here given the strong capital return potential via share appreciation. The primary risk is a mean reversion if growth slows, but the current setup favors a tactical long position with tight stops.